J07BN02 · Anti-infectives for systemic use
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
Indications
Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Composition
- Active substance
- ChAdOx1-SARS-COV-2
- International name (INN)
- COVID-19 Vaccine (ChAdOx1-S [recombinant])
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
- Active substance
- ChAdOx1-SARS-COV-2
- ATC code
- J07BN02
- Therapeutic area
- COVID-19 virus infection